Resting energy metabolism and anticancer treatments.

Anne Jouinot, Clara Vazeille, François Goldwasser

Journal: Current opinion in clinical nutrition and metabolic care 2019;21(3):145-151

PMID: 29369114

Abstract

PURPOSE OF REVIEW

Cachexia is a multifactorial syndrome associated with morbidity and mortality in cancer patients and represents a major challenge in cancer management. Elevated energy expenditure is supposed to contribute to cachexia. The current article presents the recent findings on the resting energy expenditure (REE) in cancer and the clinical implications for anticancer treatments.

RECENT FINDINGS

Half of cancer patients present with hypermetabolism (measured REE >110% of predicted REE). Hypermetabolism is associated with clinical and biological features of cachexia. Hypermetabolic patients - even those with normal nutritional status - have a high risk of severe acute toxicity and a poor prognosis.

SUMMARY

Recent discoveries have highlighted the REE as an essential component of nutritional assessment in cancer patients. Multimodal care for cachexia should include REE measurements and dedicated pharmacologic interventions such as adrenoreceptor blockade in case of hypermetabolism.

Address: Medical Oncology Department, Cancer Research for PErsonalized Medicine (CARPEM), hôpital Cochin, Paris Centre Teaching Hospitals, Paris Descartes University, USPC.; Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris, France.

DOI: 10.1097/MCO.0000000000000457

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/29369114

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Basal Metabolism, Cachexia, Energy Metabolism, Humans, Neoplasms, Nutritional Status, Rest